Hyundai Bioscience Initiates Global Clinical Trials for Dengue Antiviral, Pursuing Emergency Use Authorization

SEOUL, South Korea, April 19, 2024  — South Korea’s biotechnology company Hyundai Bioscience announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection. “The fundamental way to deal with Dengue fever is taking the antiviral drug, which is effective on all four serotypes of the Dengue virus, in the

Read more